February 24, 2017 3:48 PM ET

Biotechnology

Company Overview of United Therapeutics Corporation

Company Overview

United Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening diseases worldwide. The company’s product candidates include Remodulin, a continuously-infused formulation of the prostacyclin analogue treprostinil for subcutaneous and intravenous administration to diminish symptoms associated with exercise in pulmonary arterial hypertension (PAH) patients; Tyvaso, an inhaled formulation of treprostinil to enhace the exercise ability in PAH patients; Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; and Adcirca, a once-daily PDE-5 inhib...

1040 Spring Street

Silver Spring, MD 20910

United States

Founded in 1996

Phone:

301-608-9292

Key Executives for United Therapeutics Corporation

Founder, Chairman of the Board and Chief Executive Officer
Age: 61
Total Annual Compensation: $1.1M
Chief Financial Officer and Treasurer
Age: 48
Total Annual Compensation: $380.1K
Executive Vice President, General Counsel and Corporate Secretary
Age: 52
Total Annual Compensation: $760.2K
Senior Advisor
Age: 54
Total Annual Compensation: $925.0K
Compensation as of Fiscal Year 2015.

United Therapeutics Corporation Key Developments

United Therapeutics Mulls Acquisitions

United Therapeutics Corporation (NasdaqGS:UTHR) is looking for acquisitions. Chief Executive Officer, Martine Rothblatt, commented " We still looking at potential mergers and acquisitions to help grow the company's revenue streams, but declined to discuss specifics. The company was more aggressive on research and development and business development in the second half of 2016. We are looking at opportunities that could use up substantially all of the borrowing authority or cash in the bank that we have right now. So we still would be very cautious about spending $1 billion plus on an acquisition."

United Therapeutics Corporation Reports Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2016; Reports Impairment Charges for the Fourth Quarter Ended December 31, 2016

United Therapeutics Corporation reported consolidated earnings results for the fourth quarter and full year ended December 31, 2016. For the quarter, the company reported total revenue of $409.0 million compared to $404.9 million a year ago. Operating income was $174.2 million compared to $155 million a year ago. Income before income taxes was $171.5 million compared to $156 million a year ago. Net income was $110.3 million compared to $104.6 million a year ago. Diluted net income per share was $2.43 compared to $2.10 a year ago. Non-GAAP earnings were $187.2 million compared to $189.1 million a year ago. Diluted Non-GAAP earnings per share were $4.12 compared to $3.80 a year ago. For the full year, the company reported total revenue of $1,598.8 million compared to $1,460.6 million a year ago. Operating income was $1,061.7 million compared to $699.0 million a year ago. Income before income taxes was $1,060.2 million compared to $1,044.4 million a year ago. Net income was $713.7 million compared to $651.6 million a year ago. Diluted net income per share was $15.25 compared to $12.72 a year ago. Non-GAAP earnings were $748.6 million compared to $631.7 million a year ago. Diluted Non-GAAP earnings per share were $16.00 compared to $12.33 a year ago. For the fourth quarter ended December 31, 2016, the company reported impairment charges of $4.3 million.

United Therapeutics Corporation to Report Q4, 2016 Results on Feb 22, 2017

United Therapeutics Corporation announced that they will report Q4, 2016 results at 9:00 AM, Eastern Standard Time on Feb 22, 2017

Similar Private Companies By Industry

Company Name Region
20n Labs, Inc. United States
23andMe, Inc. United States
2C Tech Corporation, Inc. United States
3-V Biosciences, Inc. United States
3Bar Biologics Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Bloomberg L.P. United States
The Advertising Council, Inc. United States
Rush University United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact United Therapeutics Corporation, please visit www.unither.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.